Risk of Infections in Multiple Myeloma Patients Treated with Bispecific Antibodies
Cani L, Scott S, Joseph N, Hofmeister C, Gupta V, Dhodapkar M, Lonial S, Nooka A, Kaufman J. Risk of Infections in Multiple Myeloma Patients Treated with Bispecific Antibodies. Blood 2024, 144: 3311. DOI: 10.1182/blood-2024-206155.Peer-Reviewed Original ResearchRelapsed refractory multiple myelomaGrade 3 infectionLines of therapyChimeric antigen receptor T-cell therapyEpstein-Barr virusIntravenous immunoglobulinCytomegalovirus reactivationFollow-upRisk of infectionInfectious complicationsTreatment of relapsed refractory multiple myelomaMedian age of ptsUsage of intravenous immunoglobulinBispecific antibodiesNext line of therapyEpstein-Barr virus reactivationGrade 3 eventsMedian prior linesMonthly intravenous immunoglobulinGrade 3 neutropeniaT-cell therapyData cut-offRefractory multiple myelomaMedian follow-upAssociated with significant riskSingle Center Institutional Experience and Outcomes Administering Both Anti-BCMA and Anti-GPRC5D Bispecific T-Cell Engagers
Allada S, Gupta V, Hofmeister C, Kaufman J, Dhodapkar M, Lonial S, Nooka A, Joseph N. Single Center Institutional Experience and Outcomes Administering Both Anti-BCMA and Anti-GPRC5D Bispecific T-Cell Engagers. Blood 2024, 144: 7861. DOI: 10.1182/blood-2024-210996.Peer-Reviewed Original ResearchB-cell maturation antigenRefractory myelomaAnti-BCMABispecific antibodiesInternational Myeloma Working Group Uniform Response CriteriaInstitutional experienceWinship Cancer Institute of Emory UniversityCAR-T cell therapyBispecific T-cell engagerSignificant tumor burdenT-cell engagersDecreased performance statusWinship Cancer InstituteRate of gradeLimited treatment optionsStatistically significant differenceMedian PFSPretreated patientsCAR-TMedian followResponse CriteriaTumor burdenPretreated populationDose reductionMaturation antigen